68,000 Shares in Innoviva, Inc. (NASDAQ:INVA) Bought by Chase Investment Counsel Corp

Chase Investment Counsel Corp bought a new stake in shares of Innoviva, Inc. (NASDAQ:INVA - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 68,000 shares of the biotechnology company's stock, valued at approximately $1,090,000. Chase Investment Counsel Corp owned 0.11% of Innoviva at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. PNC Financial Services Group Inc. increased its position in shares of Innoviva by 2.7% during the third quarter. PNC Financial Services Group Inc. now owns 46,109 shares of the biotechnology company's stock worth $599,000 after acquiring an additional 1,234 shares during the period. Tokio Marine Asset Management Co. Ltd. raised its position in Innoviva by 11.1% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 12,000 shares of the biotechnology company's stock valued at $156,000 after purchasing an additional 1,200 shares in the last quarter. Pacer Advisors Inc. raised its position in Innoviva by 119,140.3% in the 4th quarter. Pacer Advisors Inc. now owns 1,728,984 shares of the biotechnology company's stock valued at $27,733,000 after purchasing an additional 1,727,534 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of Innoviva by 71.4% in the 3rd quarter. Jennison Associates LLC now owns 85,071 shares of the biotechnology company's stock valued at $1,105,000 after buying an additional 35,430 shares during the period. Finally, Boston Partners grew its position in shares of Innoviva by 10.2% during the third quarter. Boston Partners now owns 393,470 shares of the biotechnology company's stock worth $5,111,000 after buying an additional 36,313 shares in the last quarter. 99.12% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

INVA has been the topic of several analyst reports. TheStreet raised shares of Innoviva from a "c" rating to a "b-" rating in a report on Thursday, February 29th. StockNews.com upgraded shares of Innoviva from a "hold" rating to a "buy" rating in a report on Friday, March 29th.

Innoviva Stock Up 1.8 %

Innoviva stock traded up $0.28 during midday trading on Monday, reaching $15.54. The company's stock had a trading volume of 593,643 shares, compared to its average volume of 674,894. The company has a market cap of $982.59 million, a P/E ratio of 7.13 and a beta of 0.57. The company has a quick ratio of 7.96, a current ratio of 9.03 and a debt-to-equity ratio of 0.66. The business has a 50-day simple moving average of $15.00 and a 200-day simple moving average of $14.96. Innoviva, Inc. has a fifty-two week low of $11.37 and a fifty-two week high of $16.86.

Innoviva (NASDAQ:INVA - Get Free Report) last issued its earnings results on Thursday, February 29th. The biotechnology company reported $0.76 earnings per share for the quarter. The business had revenue of $85.84 million for the quarter. Innoviva had a return on equity of 30.37% and a net margin of 57.89%.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.